id	sid	eid	entity	type
dti-2637	1	1	dti	ORG
dti-2637	1	2	2024	CARDINAL
dti-2637	1	3	18	CARDINAL
dti-2637	1	4	4	CARDINAL
dti-2637	1	5	1177-3928	CARDINAL
dti-2637	1	6	10.33393	CARDINAL
dti-2637	1	7	1177-3928	CARDINAL
dti-2637	1	8	2024	CARDINAL
dti-2637	2	1	4.0	CARDINAL
dti-2637	5	1	popova3	PRODUCT
dti-2637	5	2	evgeny grigoryev4	ORG
dti-2637	5	3	tatyana dronova1	PERSON
dti-2637	5	4	polina gervas1	ORG
dti-2637	5	5	alexey dobrodeev5	PERSON
dti-2637	5	6	dmitry kostromitskiy5	PERSON
dti-2637	5	7	goldberg3	PERSON
dti-2637	5	8	sergey afanasiev5	PERSON
dti-2637	6	1	tomsk national research medical center	ORG
dti-2637	6	2	russian academy of sciences	ORG
dti-2637	6	3	tomsk russian federation	ORG
dti-2637	7	1	2siberian	NORP
dti-2637	7	2	tomsk russian federation	ORG
dti-2637	7	3	tomsk national research medical center	ORG
dti-2637	7	4	russian academy of sciences	ORG
dti-2637	7	5	tomsk russian federation	ORG
dti-2637	7	6	tomsk national research medical center	ORG
dti-2637	7	7	russian academy of sciences	ORG
dti-2637	7	8	tomsk russian federation	ORG
dti-2637	7	9	tomsk national research medical center	ORG
dti-2637	7	10	russian academy of sciences	ORG
dti-2637	7	11	tomsk russian federation	ORG
dti-2637	8	1	nivolumab	PERSON
dti-2637	8	2	1	CARDINAL
dti-2637	8	3	1/2	CARDINAL
dti-2637	9	1	the us food and drug administration	ORG
dti-2637	9	2	fda	ORG
dti-2637	9	3	msi-high)/deficiencies	DATE
dti-2637	11	1	42-year-old	DATE
dti-2637	11	2	antiangiogenic	NORP
dti-2637	12	1	first	ORDINAL
dti-2637	12	2	8 months	DATE
dti-2637	14	1	july 19	DATE
dti-2637	14	2	2023	CARDINAL
dti-2637	14	3	january 8, 2024	DATE
dti-2637	14	4	january 23, 2024	DATE
dti-2637	15	1	1	CARDINAL
dti-2637	15	2	cd28	ORG
dti-2637	16	1	1/2	CARDINAL
dti-2637	16	2	1	CARDINAL
dti-2637	17	1	nivolumab	PERSON
dti-2637	18	1	nivolumab	PERSON
dti-2637	18	2	142	CARDINAL
dti-2637	18	3	2	CARDINAL
dti-2637	19	1	68.9%	PERCENT
dti-2637	19	2	31.1%	PERCENT
dti-2637	19	3	2	CARDINAL
dti-2637	21	1	nivolumab	PERSON
dti-2637	21	2	one	CARDINAL
dti-2637	21	3	first	ORDINAL
dti-2637	21	4	the us food and drug administration	ORG
dti-2637	21	5	fda	ORG
dti-2637	21	6	2017	DATE
dti-2637	21	7	babyshkina et al	PERSON
dti-2637	21	8	2024	CARDINAL
dti-2637	21	9	18	CARDINAL
dti-2637	21	10	5	CARDINAL
dti-2637	21	11	2024	DATE
dti-2637	22	1	3	CARDINAL
dti-2637	23	1	approximately 95%	PERCENT
dti-2637	23	2	4,5	CARDINAL
dti-2637	26	1	6	CARDINAL
dti-2637	28	1	7-9	DATE
dti-2637	29	1	second	ORDINAL
dti-2637	29	2	antiangiogenic	NORP
dti-2637	30	1	42-year-old	DATE
dti-2637	30	2	august 2017	DATE
dti-2637	34	1	tomsk cancer research institute	ORG
dti-2637	36	1	iiic	GPE
dti-2637	37	1	a month later	DATE
dti-2637	37	2	october 2017	DATE
dti-2637	39	1	krasp.g12d	GPE
dti-2637	40	1	msh6	ORG
dti-2637	41	1	1a	CARDINAL
dti-2637	42	1	three	CARDINAL
dti-2637	42	2	1b	CARDINAL
dti-2637	43	1	two	CARDINAL
dti-2637	44	1	first	ORDINAL
dti-2637	44	2	day 1	DATE
dti-2637	44	3	85 mg/m2	QUANTITY
dti-2637	44	4	day 1	DATE
dti-2637	44	5	400 mg/m2	QUANTITY
dti-2637	44	6	day 1	DATE
dti-2637	44	7	5-fluorouracil	QUANTITY
dti-2637	44	8	46-hour	TIME
dti-2637	44	9	5-fluorouracil 2,400 mg/m2	QUANTITY
dti-2637	44	10	day 1	DATE
dti-2637	45	1	four	CARDINAL
dti-2637	45	2	1.1	CARDINAL
dti-2637	46	1	june 2018	DATE
dti-2637	46	2	14	CARDINAL
dti-2637	46	3	up to 7 mm	QUANTITY
dti-2637	47	1	cea	ORG
dti-2637	47	2	ca19-9	PRODUCT
dti-2637	48	1	1	CARDINAL
dti-2637	48	2	mmr	ORG
dti-2637	49	1	mlh1, msh2	GPE
dti-2637	49	2	msh6	ORG
dti-2637	49	3	pms2	NORP
dti-2637	49	4	nr21	PRODUCT
dti-2637	49	5	nr-24	PRODUCT
dti-2637	49	6	bat25	ORG
dti-2637	50	1	mmr =	PERSON
dti-2637	51	1	cancer6	ORG
dti-2637	52	1	2024	DATE
dti-2637	54	1	1177-3928	CARDINAL
dti-2637	54	2	0-3.40 ng	MONEY
dti-2637	54	3	cea	ORG
dti-2637	54	4	0	CARDINAL
dti-2637	54	5	ca19-9	EVENT
dti-2637	55	1	second	ORDINAL
dti-2637	55	2	4 mg/kg	QUANTITY
dti-2637	55	3	day 1	DATE
dti-2637	55	4	day 1	DATE
dti-2637	55	5	400 mg/m2	QUANTITY
dti-2637	55	6	day 1	DATE
dti-2637	55	7	5-fluorouracil	QUANTITY
dti-2637	55	8	46-hour	TIME
dti-2637	55	9	5-fluorouracil 2,400 mg/m2	QUANTITY
dti-2637	56	1	three	CARDINAL
dti-2637	57	1	2	CARDINAL
dti-2637	58	1	seven	CARDINAL
dti-2637	59	1	105	CARDINAL
dti-2637	59	2	nine	CARDINAL
dti-2637	61	1	approximately 2 months later	DATE
dti-2637	61	2	2a	CARDINAL
dti-2637	62	1	nivolumab	PERSON
dti-2637	62	2	240 mg	PRODUCT
dti-2637	62	3	december 2018	DATE
dti-2637	63	1	three months later	DATE
dti-2637	63	2	1-2 mm	QUANTITY
dti-2637	64	1	may 2019	DATE
dti-2637	64	2	2b	CARDINAL
dti-2637	65	1	15×12 mm	QUANTITY
dti-2637	65	2	2c	CARDINAL
dti-2637	66	1	10	CARDINAL
dti-2637	67	1	1b	CARDINAL
dti-2637	68	1	nivolumab	ORG
dti-2637	69	1	2d	DATE
dti-2637	69	2	august 2019	DATE
dti-2637	70	1	2e	CARDINAL
dti-2637	71	1	september 2021	DATE
dti-2637	71	2	covid-19	GPE
dti-2637	73	1	fig	ORG
dti-2637	73	2	2	CARDINAL
dti-2637	74	1	5 months	DATE
dti-2637	74	2	up to	QUANTITY
dti-2637	74	3	12 mm	QUANTITY
dti-2637	74	4	8 months	DATE
dti-2637	74	5	40 months	DATE
dti-2637	75	1	babyshkina et al	PERSON
dti-2637	75	2	2024	CARDINAL
dti-2637	75	3	18	CARDINAL
dti-2637	75	4	7	CARDINAL
dti-2637	75	5	2024	DATE
dti-2637	76	1	april 2022	DATE
dti-2637	76	2	7 mm	QUANTITY
dti-2637	76	3	2f	CARDINAL
dti-2637	77	1	day 1	DATE
dti-2637	77	2	85 mg/m2	QUANTITY
dti-2637	77	3	day 1	DATE
dti-2637	77	4	400 mg/m2	QUANTITY
dti-2637	77	5	day 1	DATE
dti-2637	77	6	5-fluorouracil	QUANTITY
dti-2637	77	7	48 hours	TIME
dti-2637	77	8	5-fluorouracil 2,400 mg/m2	QUANTITY
dti-2637	77	9	day 1	DATE
dti-2637	78	1	three	CARDINAL
dti-2637	78	2	2,500 mg	QUANTITY
dti-2637	79	1	10	CARDINAL
dti-2637	80	1	antiangiogenic	NORP
dti-2637	80	2	32 months	DATE
dti-2637	81	1	pd-1/pd-l1	ORG
dti-2637	85	1	helsinki	PERSON
dti-2637	86	1	the ethics committee of the cancer research institute	ORG
dti-2637	86	2	tomsk national research medical center	ORG
dti-2637	86	3	01/19/22	CARDINAL
dti-2637	88	1	the russian science foundation	ORG
dti-2637	88	2	#	CARDINAL
dti-2637	88	3	22-15-00212	TIME
dti-2637	90	1	evgeny grigoryev	PERSON
dti-2637	90	2	tatyana dronova	PERSON
dti-2637	90	3	polina gervas	PERSON
dti-2637	90	4	alexey dobrodeev	PERSON
dti-2637	90	5	dmitry kostromitskiy	ORG
dti-2637	90	6	victor goldberg	PERSON
dti-2637	90	7	sergey afanasiev	PERSON
dti-2637	91	1	first	ORDINAL
dti-2637	91	2	nataliya babyshkina	PERSON
dti-2637	91	3	nataliya popova	ORG
dti-2637	93	1	1	CARDINAL
dti-2637	94	1	xiao y,	PERSON
dti-2637	94	2	freeman gj	PERSON
dti-2637	97	1	2015;5(1):16	CARDINAL
dti-2637	98	1	2	CARDINAL
dti-2637	99	1	overman mj	PERSON
dti-2637	99	2	mcdermott	PERSON
dti-2637	99	3	nivolumab	PERSON
dti-2637	99	4	142	CARDINAL
dti-2637	99	5	2	CARDINAL
dti-2637	101	1	2017;18(9):1182-1191	CARDINAL
dti-2637	102	1	3	CARDINAL
dti-2637	103	1	overman mj	PERSON
dti-2637	103	2	bergamo f	PERSON
dti-2637	103	3	mcdermott rs	PERSON
dti-2637	103	4	nivolumab	PERSON
dti-2637	104	1	j clin oncol	PERSON
dti-2637	105	1	554–554	CARDINAL
dti-2637	106	1	4	CARDINAL
dti-2637	106	2	fakih m	PERSON
dti-2637	106	3	raghav kps	PERSON
dti-2637	106	4	chang dz	PERSON
dti-2637	106	5	2	CARDINAL
dti-2637	108	1	2023;58:101917	CARDINAL
dti-2637	109	1	5	CARDINAL
dti-2637	110	1	saunders mp	PERSON
dti-2637	110	2	graham j	PERSON
dti-2637	113	1	2022;7(6):100594	CARDINAL
dti-2637	114	1	6	CARDINAL
dti-2637	115	1	humbert o	PERSON
dti-2637	115	2	chardin	NORP
dti-2637	115	3	d.	NORP
dti-2637	117	1	2020;10:566297	CARDINAL
dti-2637	117	2	7	CARDINAL
dti-2637	118	1	wong	PERSON
dti-2637	118	2	vellayappan	GPE
dti-2637	118	3	cheng l	PERSON
dti-2637	121	1	2021;13(7):1689	CARDINAL
dti-2637	122	1	8	CARDINAL
dti-2637	123	1	mezquita l	ORG
dti-2637	123	2	1.1	CARDINAL
dti-2637	125	1	2018;88:38	CARDINAL
dti-2637	126	1	crossref	ORG
dti-2637	126	2	9	CARDINAL
dti-2637	127	1	sato y	PERSON
dti-2637	129	1	2021;39(4):1170-1178	CARDINAL
dti-2637	130	1	crossref	ORG
dti-2637	130	2	10	CARDINAL
dti-2637	131	1	seymour l	PERSON